Profil bibliographique

Philip J. Ebert

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

129Publications signalées

4990Citations signalées

1Affiliations récentes

Institutions déclarées

Eli Lilly (United States)

Domaines associés

Advanced Breast Cancer TherapiesSarcoma Diagnosis and TreatmentLung Cancer Research StudiesCancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Publications récentes

Accès ouvert 2025 articleOpenAlex

Survival benefit from abemaciclib in non–small cell lung cancer by Kirsten rat sarcoma–mutation gene expression subtype: retrospective analysis from the JUNIPER Trial

Jiangang Liu, Hong Wang, Amit Aggarwal, María Jesús Ortiz-Ruiz et autres

2 citationsFrontiers in Oncology

Accès ouvert 2024 otherOpenAlex

Data from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Figure S2 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S5 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S4 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Figure S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Figure S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S5 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S7 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Accès ouvert 2024 supplementary-materialsOpenAlex

Supplementary Table S6 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE

Jiangang Liu, David S. Moura, Robin L. Jones, Amit Aggarwal et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.